Claims

1. An immunogenic composition comprising, relative to the total volume of the composition:

   a. 0.05 mg/mL to 5 mg/mL of an HIV gp140 protein or of a mixture of at least two HIV gp140 proteins;
   b. 2% to 15% (w/v) sorbitol;
   c. 0.01 to 0.05% (w/v) polysorbate 20; and
   d. 5 to 20 mM histidine buffer at a pH of 5.5 to 7.0.

2. The immunogenic composition of claim 1, wherein the concentration of the HIV gp140 protein or of the mixture of HIV gp140 proteins is 0.2 mg/mL.

3. The immunogenic composition of claim 1, wherein the concentration of the HIV gp140 protein or of the mixture of HIV gp140 proteins is 1 mg/mL.

4. The immunogenic composition of any one of claims 1-3, wherein the concentration of sorbitol is 5% (w/v).

5. The immunogenic composition of any one of claims 1-3, wherein the concentration of sorbitol is 12% (w/v).

6. The immunogenic composition of any one of claims 1-5, wherein the concentration of polysorbate 20 is 0.02% (w/v).

7. The immunogenic composition of any one of claims 1-6, wherein the concentration of the histidine buffer is 10 mM, and the pH of the histidine buffer is 6.5.

8. The immunogenic composition of any one of claims 1-7, further comprising aluminum phosphate adjuvant, e.g. at 0.7-4.0 mg/mL, e.g. at 0.85 mg/mL or 3.84 mg/mL.

9. The immunogenic composition of any one of claims 1-8, wherein the HIV gp140 protein comprises the amino acid sequence of SEQ ID NO: 1.

10. The immunogenic composition of any one of claims 1-8, wherein the HIV gp140 protein comprises the amino acid sequence of SEQ ID NO: 2.

11. The immunogenic composition of any one of claims 1-8, comprising a mixture of an HIV gp140 protein comprising the amino acid *sequence* of SEQ ID NO:1 and an HIV gp140 protein comprising the amino acid sequence of SEQ NO: 2.

12. An immunogenic composition comprising, relative to the total volume of the composition,

a. 0.2 mg/mL or 1 mg/mL of an HIV gp140 protein comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 or of a mixture of an HIV gp140
a. protein comprising the amino acid sequence of SEQ ID NO:1 and an HIV
a. gp140 protein comprising the amino acid sequence of SEQ NO: 2;
b. 5% or 12% (w/v) sorbitol;
c. 0.02% (w/v) polysorbate 20;
d. 10 mM histidine buffer at a pH of 6.5; and
e. aluminum phosphate adjuvant, e.g. 0.85 mg/mL or 3.84 mg/mL.

13. A method of preparing an immunogenic composition comprising admixing:

a. 0.05 mg/mL to 5 mg/mL of an HIV gp140 protein or of at least two HIV gp140 proteins;
b. 2% to 15% (w/v) sorbitol;
c. 0.01 to 0.05% polysorbate 20; and
d. 5 to 20 mM histidine buffer at a pH of 5.5 to 7.0;

to thereby obtain the immunogenic composition.

14. The method according to claim 13, further comprising admixing:
e.g. 0.7-4.0 mg/mL aluminum phosphate adjuvant.

15. The immunogenic composition of any one of claims 1-12, which is stable upon storage at 2-8°C for at least six months.

16. A method for preparing a long-term, storage stable immunogenic composition that comprises HIV gp140 protein, the method comprising: (i) providing an immunogenic composition according to any one of claims 1-12 or 15, and (ii) storing said composition at 2-8°C for at least one week, e.g. at least one month, e.g. 1-72 months, e.g. 6-48 months, e.g. 12-36 months, e.g. 18-30 months.